We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Active Compound in Popular Heartburn Drug Pepcid Being Tested for COVID-19 Treatment

By HospiMedica International staff writers
Posted on 29 Apr 2020
Print article
Illustration
Illustration
A trial for famotidine, the active compound in the over-the-counter heartburn medication Pepcid, is underway at the Feinstein Institutes for Medical Research (Manhasset, NY, USA) to study if the drug can make a difference in the treatment of COVID-19 patients.

The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.

Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.

The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,

The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.

Related Links:
Feinstein Institutes for Medical Research

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
LED Phototherapy System
Bililed Mini+

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.